$7.4 Billion, Take Two: The New Purdue Pharma and Sackler Settlement

A bipartisan coalition of state attorneys general announced a $7.4 billion settlement in principle on January 23, 2025, with Purdue Pharma, Inc. and members of the Sackler family who own the company, resolving thousands of lawsuits over the company's role in fueling the American opioid crisis and replacing an earlier settlement the U.S. Supreme Court had invalidated seven months prior.DOCUMENTED

The new agreement adds $1.4 billion beyond the prior $6 billion settlement rejected by the Supreme Court in June 2024, and all 50 states, the District of Columbia, and U.S. territories had approved the revised plan by mid-2025, with a bankruptcy court confirming the plan later that year.DOCUMENTED

Why the original deal collapsed

The prior $6 billion settlement, reached through Purdue's bankruptcy proceedings, had included a provision granting members of the Sackler family broad immunity from civil lawsuits related to the opioid crisis, even though the Sacklers themselves had not personally filed for bankruptcy protection — only their company had. Several states, including California, Connecticut, Delaware, Maryland, Oregon, Rhode Island, Vermont, and Washington, along with the District of Columbia, objected to and ultimately appealed that arrangement, arguing that bankruptcy courts lacked authority to force non-bankrupt individuals' creditors to release their legal claims.DOCUMENTED

The U.S. Supreme Court sided with the dissenting states in June 2024, ruling that the bankruptcy code does not authorize a release of claims against non-debtor third parties like the Sacklers without the claimants' consent, effectively invalidating the entire settlement structure and sending negotiators back to the table.DOCUMENTED

Renegotiating a bigger deal

Connecticut, New York, California, and eleven other states led a bipartisan negotiating team through active mediation following the Supreme Court's ruling, ultimately reaching a new settlement in principle in January 2025 worth up to $7.4 billion — roughly $1.4 billion more than the invalidated prior deal. Connecticut Attorney General William Tong, whose office announced the agreement alongside the other negotiating states, framed the larger figure as reflecting both additional funds extracted from the Sacklers and an accelerated payment schedule designed to get resources to states and victims more quickly than the original structure would have allowed.DOCUMENTED

Under the new agreement, the Sacklers will pay up to $6.5 billion over 15 years, while Purdue Pharma itself will contribute nearly $900 million. New York Attorney General Letitia James, whose office led the negotiations to secure court approval of the final bankruptcy plan, said the settlement holds "the Sackler family accountable" for what she described as their leading role in fueling opioid addiction and overdoses through the company's marketing and sales practices.DOCUMENTED

What the settlement funds and what it doesn't

The settlement structures payments to arrive over 15 years, with a significant portion front-loaded: an initial payment of $1.5 billion, followed by $500 million after one year, another $500 million after two years, and $400 million after three years, according to New York's announcement of the terms. Funds are earmarked to support opioid addiction treatment, prevention, and recovery programs across participating states, local governments, and individual victims and their families who had previously sued the Sacklers or Purdue.DOCUMENTED

As part of the deal, the Sackler family will permanently relinquish control of Purdue Pharma. A board of trustees selected by the participating states, in consultation with other creditors, will determine the company's future operations, and Purdue will remain under ongoing monitor oversight while being barred from lobbying on opioid-related policy or continuing to market opioid products.DOCUMENTED

Part of a far larger reckoning

The Purdue settlement is one piece of a much larger wave of opioid litigation that has produced roughly $50 billion in combined settlements from manufacturers, distributors, and pharmacy chains in recent years, according to figures cited alongside the announcement. New York Attorney General James's office has separately led multistate coalitions securing settlements with companies including Mylan, Indivior, Amneal Pharmaceuticals, Hikma Pharmaceuticals, Teva Pharmaceuticals, Johnson & Johnson, Mallinckrodt, Allergan, Endo, McKesson, Cardinal Health, and AmerisourceBergen, along with pharmacy chains CVS, Walgreens, and Walmart over allegations they failed to properly monitor and flag suspicious opioid prescriptions.REVIEWED

For families who lost loved ones to opioid overdoses tied to OxyContin, the settlement's scale, while historic, does not undo the underlying harm the litigation was built around: internal Purdue marketing documents surfaced across years of litigation showed the company aggressively promoted OxyContin's supposed low risk of addiction to physicians even as internal data suggested otherwise, a pattern of alleged deception that shaped the opioid epidemic's early trajectory well before regulators or the public understood its scale.

The Supreme Court's intervention in this case also carries implications well beyond Purdue itself, since the ruling curtailed a bankruptcy strategy — non-debtor third-party releases — that other companies facing mass tort liability had begun using as a template for their own bankruptcy filings. Future defendants seeking to use a subsidiary's or affiliate's bankruptcy proceeding to shield individual family owners or executives from liability now face a considerably higher legal bar following the Purdue ruling, making this settlement not just a resolution of the opioid litigation itself but a lasting precedent shaping how mass-tort bankruptcies are structured going forward.REVIEWED

Court approval of the revised bankruptcy plan in late 2025 cleared the way for the first payments to begin reaching states and individual victims in early 2026, closing out more than half a decade of litigation and appeals that began with Purdue's original 2019 bankruptcy filing and wound through multiple rounds of negotiation before finally surviving Supreme Court review on its second attempt.REVIEWED

Have documents relevant to this story? Reach us through our tips channel.